Key points are not available for this paper at this time.
ACY-1215 is an oral selective HDAC6 inhibitor that was safe in patients with relapsed and refractory lymphoid malignancies and led to disease stabilization in half of the evaluable patients.
Amengual et al. (Mon,) studied this question.